SCHEMBL92626

SCHEMBL92626

C1CN(CC2CC2)CCN1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 2/20 0.48
ADRA2C P18825 1/20 0.48
ACHE P22303 1/20 0.41
GBA1 P04062 2/20 0.40
RAD52 P43351 1/20 0.39
CNR1 P21554 1/20 0.39
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CACNA2D1 P54289 1/20 0.37
CACNA1B Q00975 1/20 0.37
CACNB1 Q02641 1/20 0.37
SIGMAR1 Q99720 3/20 0.37
CXCR4 P61073 2/20 0.37
CHRM3 P20309 1/20 0.36
SCN1A P35498 1/20 0.35
SCN4A P35499 1/20 0.35
SCN7A Q01118 1/20 0.35
KCNH2 Q12809 1/20 0.35
SCN5A Q14524 1/20 0.35
SCN9A Q15858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL731212 1.00 CHRM5 (0.48) CHRM5ADRA2CACHEGBA1RAD52
SCHEMBL2912326 1.00 CHRM5 (0.48) CHRM5ADRA2CACHEGBA1RAD52
SCHEMBL20873850 1.00 CHRM5 (0.48) CHRM5ADRA2CACHEGBA1RAD52
Bromide SCHEMBL31114948 0.97 CHRM5 (0.46) CHRM5ADRA2CACHEGBA1RAD52
Hydrochloric Acid SCHEMBL21001940 0.97 CHRM5 (0.46) CHRM5ADRA2CACHEGBA1RAD52
Hydrochloric Acid SCHEMBL4668199 0.97 CHRM5 (0.46) CHRM5ADRA2CACHEGBA1RAD52
Hydrochloric Acid SCHEMBL5570644 0.97 CHRM5 (0.46) CHRM5ADRA2CACHEGBA1RAD52
SCHEMBL2570307 0.92 GBA1 (0.47) CHRM5ADRA2CACHEGBA1RAD52
SCHEMBL1268833 0.91 ADRA2C (0.52) CHRM5ADRA2CACHEGBA1RAD52
SCHEMBL211956 0.90 CHRM5 (0.56) CHRM5ADRA2CACHEGBA1RAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 836 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119391811-A Application of piperazine derivative in bacteriostasis of spoilage bacteria 黄河科技学院 2025-02-07 CN claimed
CN-118684644-A Eupatilin derivative containing piperazine structure and preparation method and application thereof 南阳医学高等专科学校 2024-09-24 CN claimed
US-11787785-B2 Pyrazolopyridine derivatives and uses thereof NOVARTIS AG (CH) 2023-10-17 US claimed
US-20230108325-A1 Pyrazolopyridine Derivatives and Uses thereof NOVARTIS AG (CH) 2023-04-06 US claimed
CN-108341792-B Preparation method of Volasertib intermediate 1-cyclopropyl methyl piperazine 苏州莱克施德药业有限公司 2021-09-17 CN claimed
CN-113200908-A Tertiary amine-containing anthranilamide compound and preparation and application thereof 南华大学 2021-08-03 CN claimed
CN-106660955-A Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient 现代药品株式会社 2017-05-10 CN claimed
EP-3044210-A2 NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE Cortendo AB (publ) (US) 2016-07-20 EP claimed
US-20140273458-A1 Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-18 US claimed
CN-104046246-A Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PROD & CHEM 2014-09-17 CN claimed
EP-1778668-B1 METHOD FOR THE PRODUCTION OF DIHYDROPTERIDINONES BOEHRINGER INGELHEIM INT (DE) 2013-07-03 EP claimed
EP-2010496-B1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2010-08-25 EP claimed
US-20090054411-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2009-02-26 US claimed
EP-2010496-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS AstraZeneca AB (SE) 2009-01-07 EP claimed
WO-2007119046-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2007-10-25 WO claimed
US-6355635-B1 IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY PFIZER INC. 2002-03-12 US claimed
US-20010039277-A1 Compounds for the treatment of obesity ELLIOTT RICHARD L (US) 2001-11-08 US claimed
WO-2000066578-A1 COMPOUNDS FOR THE TREATMENT OF OBESITY PFIZER PRODUCTS INC. (US) 2000-11-09 WO claimed
EP-0050072-B1 CYCLOPROPYL METHYL PIPERAZINES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPEUTICS INNOTHERA (FR) 1984-12-27 EP claimed
EP-0050072-A1 Cyclopropyl methyl piperazines, process for their preparation and their use in therapeutics INNOTHERA (FR) 1982-04-21 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11787785-B2 Pyrazolopyridine derivatives and uses thereof HBZ, ZFX, WIZ CHRM5 4105/4885ADRA2C 2057/4885ACHE 4474/4885
US-20010039277-A1 Compounds for the treatment of obesity NPY1R, NPY4R, NPY2R CHRM5 731/4885ADRA2C 181/4885ACHE 2598/4885
US-20230108325-A1 Pyrazolopyridine Derivatives and Uses thereof HBZ, ZFX, WIZ CHRM5 4105/4885ADRA2C 2057/4885ACHE 4474/4885
US-20090054411-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS CSF1R, CSF3R, FLT3 CHRM5 2693/4885ADRA2C 2470/4885ACHE 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.